Portfolio Optimization with Digital Currencies based on Risk Parity Model: A Case Study of Bitcoin
Journal of Statistics and Economics · 2026-04 · 3 (2) · 78-84
DOI: 10.62517/jse.202611212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Statistics and Economics, 2026-04. Verfasst von Zhongxue Zhu. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
The challenges facing the traditional 60/40 portfolio have prompted exploration into digital assets like Bitcoin for diversification, despite their extreme volatility. This study investigates the integration of Bitcoin into a traditional portfolio using a risk parity approach. We construct and compare a standalone Bitcoin, a traditional 60/40 portfolio consisting of the SPTR500 index and the IEF, and a new risk parity portfolio weighted by the inverse of volatility. Employing the EGARCH(1,1) model for volatility analysis and historical simulation for Value at Risk (VaR) and Expected Shortfall (ES), the empirical results show that the new risk parity portfolio achieves a significantly higher Sharpe ratio and lower tail risk, with extreme losses between -3% and -4%. The study concludes that strategic inclusion of Bitcoin within a dynamically weighted portfolio can significantly enhance overall performance, providing empirical support for integrating digital assets.
Zitieren
APA
Zhu, Z. (2026). Portfolio Optimization with Digital Currencies based on Risk Parity Model: A Case Study of Bitcoin. Journal of Statistics and Economics, 3(2), 78-84. https://doi.org/10.62517/jse.202611212
Vancouver
Zhu Z. Portfolio Optimization with Digital Currencies based on Risk Parity Model: A Case Study of Bitcoin. Journal of Statistics and Economics. 2026;3(2):78-84. doi:10.62517/jse.202611212
BibTeX
@article{Zhu2026,
author = {Zhu, Zhongxue},
title = {Portfolio Optimization with Digital Currencies based on Risk Parity Model: A Case Study of Bitcoin},
journal = {Journal of Statistics and Economics},
year = {2026},
volume = {3},
number = {2},
pages = {78--84},
doi = {10.62517/jse.202611212}
}
EUVIMED